Erasca
ERAS · Nasdaq · United States
Share price · ERAS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ERAS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-8.1%
- 11 Nov 2026+8.5%
- 16 Oct 2026-10.0%
- 8 Oct 2026+9.5%
Nothing announced by ERAS that day or the session before.
- 26 Aug 2026+7.8%
Nothing announced by ERAS that day or the session before.
- 28 Apr 2026-48.3%
- Day beforeErasca: Other material event
- 27 Apr 2026-10.9%
- 20 Apr 2026+14.2%
Nothing announced by ERAS that day or the session before.
- 15 Jan 2026+15.0%
Nothing announced by ERAS that day or the session before.
- 13 Jan 2026+20.5%
Share of unusual movement by asset
For each asset, the share of ERAS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | pan-RASSmall molecule | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $47M | $119M+ $525M short-term inv. | $51M-$33M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $36M | $43M+ $226M short-term inv. | $44M-$27M operating cash flow | report ↗ |
| 2026-Q1 | — | $27M | $47M+ $197M short-term inv. | $183M-$27M operating cash flow | report ↗ |
| 2025-Q3 | — | $22M | $70M+ $218M short-term inv. | $31M-$22M operating cash flow | report ↗ |
| 2025-Q2 | — | $21M | $66M+ $235M short-term inv. | $34M-$21M operating cash flow | report ↗ |
| 2025-Q1 | — | $26M | $70M+ $234M short-term inv. | $31M-$32M operating cash flow | report ↗ |
| 2024-Q3 | — | $28M | $69M+ $250M short-term inv. | $31M-$22M operating cash flow | report ↗ |
| 2024-Q2 | — | $33M | $173M+ $236M short-term inv. | $63M-$29M operating cash flow | report ↗ |
| 2024-Q1 | — | $29M | $77M+ $221M short-term inv. | $35M-$33M operating cash flow | report ↗ |
| 2023-Q3 | — | $25M | $113M+ $184M short-term inv. | $30M-$24M operating cash flow | report ↗ |
| 2023-Q2 | — | $26M | $139M+ $178M short-term inv. | $32M-$26M operating cash flow | report ↗ |
| 2023-Q1 | — | $28M | $273M+ $117M short-term inv. | $33M-$26M operating cash flow | report ↗ |
| 2022-Q3 | — | $28M | $219M+ $137M short-term inv. | $35M-$24M operating cash flow | report ↗ |
| 2022-Q2 | — | $27M | $298M+ $73M short-term inv. | $36M-$27M operating cash flow | report ↗ |
| 2022-Q1 | — | $27M | $333M+ $59M short-term inv. | $36M-$26M operating cash flow | report ↗ |
| 2021-Q3 | — | $20M | $446M+ $41M short-term inv. | $46M-$23M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $93M | $74M+ $202M short-term inv. | $31M-$95M operating cash flow | report ↗ |
For FY2025, Erasca did not disclose revenue. R&D expenses were $92.854M, down 19.5% YoY from $115.359M. Cash and cash equivalents stood at $73.805M, while total cash, cash equivalents, and marketable securities were $341.8M as of December 31, 2025, compared to $440.5M at the end of 2024. The full-year net loss was $124.546M, or $(0.44) per share, versus $161.7M, or $(0.69) per share, in FY2024.
Management expects pro forma cash, cash equivalents, and marketable securities of $434M, including proceeds from the January 2026 upsized offering and net of the Joyo payment, to fund operations into H2 2028. Clinical developments include encouraging early ERAS-0015 dose-escalation data with confirmed partial responses across RAS-mutant tumors and no dose-limiting toxicities; Phase 1 monotherapy data for ERAS-0015 are expected in H1 2026 and for ERAS-4001 in H2 2026. The company also completed an upsized financing raising approximately $258.8M in gross proceeds, expanded its Joyo license to worldwide rights for ERAS-0015, and received U.S. composition-of-matter patents covering ERAS-4001 and ERAS-0015.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $115M | $68M+ $231M short-term inv. | $40M-$109M operating cash flow | report ↗ |
| 2023-FY | — | $104M | $93M+ $219M short-term inv. | $31M-$101M operating cash flow | report ↗ |
| 2022-FY | — | $112M | $284M+ $151M short-term inv. | $61M-$103M operating cash flow | report ↗ |
| 2021-FY | — | $74M | $360M+ $54M short-term inv. | $31M-$80M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 3 sales ($2.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-10 | Fuchs Charles S. · President, R&D | Award / grant (derivative) | 1,300,000 | — | — | Form 4 |
| 2026-06-26 | Bristol James Arthur · director | Award / grant (derivative) | 29,888 | — | — | Form 4 |
| 2026-06-26 | Hambleton Julie · director | Award / grant (derivative) | 29,888 | — | — | Form 4 |
| 2026-06-26 | Casdin Alexander W. · director | Award / grant (derivative) | 29,888 | — | — | Form 4 |
| 2026-06-26 | Multani Pratik S · director | Award / grant (derivative) | 29,888 | — | — | Form 4 |
| 2026-06-26 | LIU JEAN I · director | Award / grant (derivative) | 29,888 | — | — | Form 4 |
| 2026-06-26 | Start Valerie Denise Harding · director | Award / grant (derivative) | 29,888 | — | — | Form 4 |
| 2026-04-01 | Garner Ebun · Chief Legal Officer | Option exercise | 80,000 | $1.70 | $136K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 224 reporting institutions held 273.7M shares ($4.0B, 78.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 24,675,188 | $399.2M |
| 2 | BlackRock, Inc. | 20,151,406 | $326.0M |
| 3 | Venrock Adviser, LLC | 16,382,812 | $265.1M |
| 4 | RTW INVESTMENTS, LP | 16,157,175 | $261.4M |
| 5 | Vivo Capital, LLC | 12,151,480 | $196.6M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 11,249,738 | $182.0M |
| 7 | Siren, L.L.C. | 11,244,246 | $181.9M |
| 8 | Logos Global Management LP | 11,150,000 | $180.4M |
| 9 | Paradigm Biocapital Advisors LP | 10,392,702 | $168.2M |
| 10 | STATE STREET CORP | 9,300,084 | $150.5M |
| 11 | ARCH Venture Management, LLC | 7,091,557 | $114.7M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 5,996,149 | $97.0M |
| 13 | Cormorant Asset Management, LP | 5,800,000 | $93.8M |
| 14 | Affinity Asset Advisors, LLC | 5,350,000 | $86.6M |
| 15 | Balyasny Asset Management L.P. | 5,143,985 | $83.2M |